The first disposable electronic cystoscope in Boao landed, ushering in a new option for bladder tumor examination

SHANGHAI, Aug.

Currently, the largest single-use endoscope on the market has a viewing angle of 120 degrees, while the Uro-G offers a 140-degree viewing angle, as well as 210-degree and 130-degree active angles up and down, plus a 90-degree clockwise and counter-clockwise rotation angle , The doctor can flexibly operate the lens to observe the panorama of the bladder while keeping looking directly at the display screen, without additionally manipulating the endoscope to repeatedly rotate and detect in the human body.

The Uro-G is used together with the handheld Uro-3500 electronic endoscope image processor with unique design concept, and the collected images can be processed and then sent to the built-in display screen for imaging.

Uro-G Disposable Electronic Cystoscope

Traditional endoscopes need to be sterilized and reused, but there may still be germs remaining, causing hidden dangers of medical infection

Mr.

Tumor images examined and observed with Uro-G

Uro-3500 and Uro-G were designed and developed by UroViu Corporation (UroViu), and were approved by the U.

The inspection was completed by the team of Professor Kang Xinli from the Department of Urology of Hainan Provincial People's Hospital.

Mr.

1.

About UroViu Corporation

The disposable minimally invasive endoscope platform developed by UroViu with independent intellectual property rights solves cross-contamination of equipment, improves patient comfort and improves work efficiency

UroViu owns a number of core patents for disposable endoscopes, and expands its patent product portfolio by in-depth layouts around drugs, devices, and robotic-assisted surgery applications in the focused fields

Uro Viu is a leader in the development and manufacturing of single-use endoscopes and has an experienced medical device management team in Asia and the United States

About Asieris

Asieris (stock code: 688176.

The company adheres to the core driving force of innovative technologies and products, and through building its own R&D platform and core technologies, in-depth exploration of the mechanism of drug action, and efficient screening and evaluation of candidate drugs

At the same time, through independent research and development and strategic cooperation, Asieris has carried out an in-depth layout of product pipelines around diseases of the urogenital system, paid close attention to the technological frontiers and treatment development trends in this field, gained insight into and explored unmet clinical needs, and carried out forward-looking progress.

Source: Asieris